Table 3.
Summary of anticipated absolute differences comparing sodium-glucose cotransporter-2 inhibitor treatment with glucagon-like peptide-1 receptor agonist treatment per 1000 patients with diabetes type 2 and with very low to very high cardiovascular risk, treated for five years
| Risk* | All cause mortality | Cardiovascular mortality | Non-fatal myocardial infarction | Non-fatal stroke | Kidney failure | Hospital admission for heart failure | Body weight | Diabetic ketoacidosis | Serious hyperglycaemia | Genital infection |
|---|---|---|---|---|---|---|---|---|---|---|
| Very low | 1 fewer (3 fewer to 1 more) ⊕⊕⊕ |
0 fewer (2 fewer to 1 more) ⊕⊕⊕ |
1 fewer (4 fewer to 2 more) ⊕⊕⊕ |
5 more (1 more to 10 more) ⊕⊕⊕ |
0 (1 fewer to 0) ⊕⊕ |
1 fewer (2 fewer to 1 fewer) ⊕⊕⊕ |
0.47 kg lower (0.09 lower to 0.85 lower) over 6 months ⊕⊕⊕ |
1 more (0 to 3 more) ⊕⊕⊕ |
5 more (2 fewer to 19 more) ⊕⊕⊕ |
158 more (64 more to 299 more) ⊕⊕⊕⊕ |
| Low | 4 fewer (10 fewer to 4 more) ⊕⊕⊕⊕ |
2 fewer (6 fewer to 4 more) ⊕⊕⊕⊕ |
3 fewer (8 fewer to 4 more) ⊕⊕⊕⊕ |
9 more (1 more to 19 more) ⊕⊕⊕⊕ |
1 fewer (2 fewer to 2 more) ⊕⊕⊕ |
7 fewer (10 fewer to 4 fewer) ⊕⊕⊕⊕ |
||||
| Moderate | 6 fewer (17 fewer to 7 more) ⊕⊕⊕⊕ |
3 fewer (11 fewer to 6 more) ⊕⊕⊕⊕ |
5 fewer (15 fewer to 7 more) ⊕⊕⊕⊕ |
16 more (2 more to 33 more) ⊕⊕⊕⊕ |
1 fewer (5 fewer to 3 more) ⊕⊕⊕ |
18 fewer (25 fewer to 11 fewer) ⊕⊕⊕⊕ |
||||
| High | 9 fewer (24 fewer to 10 more) ⊕⊕⊕⊕ |
4 fewer (15 fewer to 8 more) ⊕⊕⊕⊕ |
5 fewer (16 fewer to 8 more) ⊕⊕⊕⊕ |
18 more (3 more to 36 more) ⊕⊕⊕⊕ |
6 fewer (21 fewer to 13 more) ⊕⊕⊕ |
24 fewer (32 fewer to 13 fewer) ⊕⊕⊕⊕ |
||||
| Very high | 13 fewer (37 fewer to 16 more) |
5 fewer (22 fewer to 12 more) |
7 fewer (24 fewer to 11 more) |
27 more (4 more to 53 more) |
10 fewer (34 fewer to 20 more) |
48 fewer (66 fewer to 27 fewer) |
Risk categories represent the following patient populations: very low=no or less than three cardiovascular risk factors; low=three or more cardiovascular risk factors; moderate=cardiovascular disease; high=chronic kidney disease (reduced glomerular filtration rate or macroalbuminuria); very high=cardiovascular disease and chronic kidney disease.
Certainty of the evidence for each estimate is shown: high certainty ⊕⊕⊕⊕; moderate certainty ⊕⊕⊕; low certainty ⊕⊕; very low certainty ⊕.